Clinical lymphoma, myeloma & leukemia · 2026
Long-Term Progression-Free Survival in Patients Treated With RVD Induction and Risk-Adapted Maintenance.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gu Lilly, Raval Om, Ji Xiyuan Angel, Joseph Nisha, Hofmeister Craig C, Gupta Vikas A, Parikh Richa, Shah Nishi, Mina Roberto, Switchenko Jeffrey, Boise Lawrence, Lonial Sagar, Nooka Ajay K, Kaufman Jonathan L
Аннотация
BACKGROUND: A subset of patients with newly diagnosed multiple myeloma (NDMM) achieves prolonged remission following modern induction and maintenance, but predictors of long-term progression-free survival (PFS) and the durability of remission beyond a decade remain incompletely defined.
METHODS: We retrospectively analyzed 1000 consecutive NDMM patients treated with lenalidomide, bortezomib, and dexamethasone (RVD) induction followed by risk-adapted maintenance from 2007 to 2016. Patients diagnosed after October 2015 were excluded to ensure ≥10 years of follow-up. Long-term progression-free survivors (LT-PFS) were defined as remaining progression-free for ≥10 years. Demographics, clinical characteristics, and outcomes were compared between LT-PFS and non-LT-PFS groups, and logistic regression identified predictors of LT-PFS. Survival was estimated by the Kaplan-Meier method, with a landmark analysis among patients progression-free at 10 years.
RESULTS: Among 774 patients analyzed, 165 (21.3%) achieved LT-PFS. Compared with non-LT-PFS patients, LT-PFS patients were younger, had lower disease stage, more favorable cytogenetics, more often received maintenance therapy, and achieved deeper responses to induction therapy. Median cohort PFS was 4.6 years, with a 10-year PFS rate of 26.2%. Landmark analysis demonstrated continued risk of late events, with 17% of LT-PFS patients experiencing progression or death beyond 10 years, and median PFS not reached.
CONCLUSION: Approximately one-fifth of NDMM patients treated with RVD-based therapy achieved sustained remission at 10 years, though a meaningful risk of late relapse persisted. Favorable disease biology, younger age, and maintenance therapy are associated with long-term PFS. These findings define a clinically relevant long-term remission state and provide a benchmark for evaluating outcomes with contemporary quadruplet regimens.
METHODS: We retrospectively analyzed 1000 consecutive NDMM patients treated with lenalidomide, bortezomib, and dexamethasone (RVD) induction followed by risk-adapted maintenance from 2007 to 2016. Patients diagnosed after October 2015 were excluded to ensure ≥10 years of follow-up. Long-term progression-free survivors (LT-PFS) were defined as remaining progression-free for ≥10 years. Demographics, clinical characteristics, and outcomes were compared between LT-PFS and non-LT-PFS groups, and logistic regression identified predictors of LT-PFS. Survival was estimated by the Kaplan-Meier method, with a landmark analysis among patients progression-free at 10 years.
RESULTS: Among 774 patients analyzed, 165 (21.3%) achieved LT-PFS. Compared with non-LT-PFS patients, LT-PFS patients were younger, had lower disease stage, more favorable cytogenetics, more often received maintenance therapy, and achieved deeper responses to induction therapy. Median cohort PFS was 4.6 years, with a 10-year PFS rate of 26.2%. Landmark analysis demonstrated continued risk of late events, with 17% of LT-PFS patients experiencing progression or death beyond 10 years, and median PFS not reached.
CONCLUSION: Approximately one-fifth of NDMM patients treated with RVD-based therapy achieved sustained remission at 10 years, though a meaningful risk of late relapse persisted. Favorable disease biology, younger age, and maintenance therapy are associated with long-term PFS. These findings define a clinically relevant long-term remission state and provide a benchmark for evaluating outcomes with contemporary quadruplet regimens.